Biosimilar drugs: These are therapeutic biological products that have similarity in quality, safety, and efficacy with a previously registered reference drug.

This article summarized the latest R&D progress of Lurbinectedin, the Mechanism of Action for Lurbinectedin, and the drug target R&D trends for Lurbinectedin.

Elicio Therapeutics has revealed encouraging initial data related to relapse-free survival from their ongoing Phase 1 investigation of their primary asset, ELI-002.

This article summarized the latest R&D progress of Lidocaine hydrochloride, the Mechanism of Action for Lidocaine hydrochloride, and the drug target R&D trends for Lidocaine hydrochloride.

Harpoon Therapeutics, Inc. has shared the interim outcomes of its Phase 1 clinical trial on the effect of single-agent HPN217 in treating relapsed or refractory multiple myeloma, focused on target dose groups from 2.15 to 12mg.

This article summarized the latest R&D progress of Letermovir, the Mechanism of Action for Letermovir, and the drug target R&D trends for Letermovir.

Akeso revealed that the FDA has approved their IND for CD47 Monoclonal Antibody (AK117) combined with Azacitidine for treating Myelodysplastic Syndromes.

This article summarized the latest R&D progress of Olopatadine hydrochloride, the Mechanism of Action for Olopatadine hydrochloride, and the drug target R&D trends for Olopatadine hydrochloride.

Adcentrx Therapeutics reports the initial dosing of a patient in the Phase 1a/b trial of ADRX-0706, an innovative ADC targeting Nectin-4, aimed to treat advanced solid tumors.

This article summarized the latest R&D progress of Ixekizumab, the Mechanism of Action for Ixekizumab, and the drug target R&D trends for Ixekizumab.

Kallyope, Inc. has commenced its Phase 2 experiment to assess K-757 and K-833.

This article summarized the latest R&D progress of Inclisiran, the Mechanism of Action for Inclisiran, and the drug target R&D trends for Inclisiran.